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Due to inappropriate or excessive use of antibiotics, multi resistance has become a global 
problem which threatens the public health. Photodynamic therapy has emerged as a promising 
and important approach in many fields of drug therapy. In recent years, many studies on 
photodynamic therapy for infections have shown promising results. One of the advantages of 
using PDT in treatment of infections is the mechanism of drug action which differs from that 
of antibiotics. This opens the door for the possibilities of treating multidrug resistant bacteria. 
PDT requires photosensitizer (PS), which are stable, nontoxic and effective. To improve the 
delivery of PS usually a delivery system which provides better stability and control of the PS. 
Polymer-based nanoparticles have been proposed as a suitable delivery system based on their 
advantages (e.g. biodegradable, less toxicity, microbial and hemostatic properties).    
A New Chemical Entity (NCE) recently developed and patented by Photocure ASA is 
expected to exhibit superior antimicrobial properties and improved wound healing.  
Chitosan lecithin nanoparticles were selected and developed as a carrier system for this new 
entity. At this stage of development, the delivery system was found to have many stability 
issues which need to be optimized in the future. The sizes of the carrier were found to be 



















På grunn av upassende eller overdreven bruk av antibiotika, har multiresistents blitt et globalt 
problem som truer folkehelsen. Fotodynamisk terapi har dukket opp som en lovende og viktig 
tilnærming på mange felt. I de senere år har mange studier på fotodynamisk terapi for 
infeksjoner vist lovende resultater. En av fordelene ved PDT benyttet i behandlingen av 
infeksjoner, er virkningsmekanisme som er forskjellig fra den for antibiotika. Dette åpner 
mulighetene for behandling av multiresistente bakterier. PDT krever fotosensibiliserende 
(PS), som er stabile, ikke-toksisk og effektivt. For å forbedre levering av PS vanligvis et 
leveringssystem som gir bedre stabilitet og frigjøring av PS blir brukt. Polymer - baserte 
nanopartikler har blitt brukt i mange studier for sine fordeler (for eksempel biologisk 
nedbrytbarhet, mindre toksisitet, antimikrobiall og hemostatik egenskaper). 
En ny kjemisk entitet (NCE) er ventet å vise overlegne antimikrobielle egenskaper og 
forbedret sårtilheling. Dette NCE er utviklet og nylig patentert av Photocure ASA 
Kitosan lecithin nanopartikler ble valgt ut til å ble vurdert for dette nye system. 
leveringssystemet ble funnet å ha mange problemer, stabiliteten av det utviklet systemet 
trenger å optimaliseres i fremtiden eller eventuelt kitosan lecithin nanopartikler utviklet med 
annen metode. Størrelsene på leveringssystemet ble funnet å være egnet, men deres 





















1. General Introduction  
Skin injuries are susceptible to infection due to the loss of the original skin barrier (Percival et 
al., 2012c). Wound injuries, especially chronic wounds, are usually infected with bacteria, and 
such contamination causes delayed wound healing and also prolongs the treatment period 
which increases the chance of development of resistance (Jori et al., 2006). One of the 
mechanisms that microorganisms use to attach to the skin injuries and survive is biofilm. The 
role of biofilms is not only to assure the attachment to the wound, but also to provide the 
  g             c              ’          y                 v            c      (Percival et 
al., 2012c). This increases the resistance to antibiotics and, immunological and chemical 
attack (Percival et al., 2012c). Due to this the antibiotics resistance is reported to be one of the 
major health problems in the world (Jori et al., 2006).  
 
Photodynamic therapy (PDT) have been showing a promising future in cancer treatment, and 
lately the interest in microbial photodynamic increased (Dai et al., 2010, Kharkwal et al., 
2011). In cancer treatment the photosensitizer, for example, is injected to the bloodstream and 
in infection, the photosensitizer is delivered directly to the infected area (Dai et al., 2009, 
Tanaka et al., 2012). For the photosensitizer to accumulate in the tumor it may take some time 
and the concentration may be different than in the infection therapy were the photosensitizers 
is directly delivered to the infected area. The last part of the treatment is the same for both; 
the area will be exposed to light which results in a damaging chemical reaction to 
photogenes/cancer cells (Tanaka et al., 2012).  
 
A New Chemical Entity (NCE) is expected to show superior antimicrobial properties and 
improved wound healing. This NCE was developed and recently patented by Photocure ASA 
and is expected to assure lack of resistance development in repeated therapy. Moreover, as it 
is destined for topical therapy onto the wounded area, the therapy is expected to be more 
efficient and accessible than to other inner parts of the body. 
 
When choosing the most suitable carrier system for NCE, chitosan has been our first choice 
due to its reported wound healing properties. Chitosan has been used extensively as a drug 
delivery device and also as a vehicle to wound injuries (Dai et al., 2011). Chitosan has various 
properties which make it very interesting polymer of natural origin; such as its natural 




ability to stimulate the wound healing processes  (Dai et al., 2011). Therefore using chitosan 
as a drug delivery system may enhance antimicrobial and healings effects of the drug, in our 





2. Introduction  
 
2.1. Skin  
The skin is the largest, self-renewing organ in the human body (Baroni et al., 2012, Wickett 
and Visscher, 2006), representing approximately 16 percent of total body weight (Wickett and 
Visscher, 2006). Skin plays an important role in protecting the internal organs from external 
environment (e.g. microbial, mechanically and chemical insults). It provides protection from 
harmful light exposure, and it plays other roles such as regulating the body temperature, limits 
passive water loss and synthesizing vitamin D (Wickett and Visscher, 2006, Baroni et al., 
2012). The skin contains blood vessels, sweat glands, hair follicles, fat lobules, sweat duct, 
muscles and   ’  structured in layers. Skin is divided in two main layers, epidermis and dermis 
(Baroni et al., 2012). The structure of the skin is demonstrated in Figure 1.  
 
 
Figure 1: Structure of the skin (El Maghraby et al., 2008) 
 
2.1.1. Epidermis 
The epidermis is divided as demonstrated in Figure 2 into 4 layers; stratum corneum (SC), 
stratum granulosum, stratum spionosum and stratum basale. Each one of those layers plays 
an important role together in providing a protective barrier, specially the outer layer (SC) 









Figure 2: Structure of the epidermis (Baroni et al., 2012) 
 
 
The cells in the basal layer are responsible for the renewal of the epidermis. The majority of 
these cells are in quiescent state, while only 15 % of the cells are constantly active. The cells 
in quiescent stat intervene when proliferation is required, for example when an injury occur 
(Baroni et al., 2012).  
 
In the epidermis layer, two types of granules are formed, keratohylain granules (contains 
protein) and lamellar bodies (contains lipids) (Wickett and Visscher, 2006). 
Keratinocytes are the predominant cell type in the epidermis which exist in the basal layer to 
the granular layer before they transformed to corneocytes (anucleate) in the SC (Wickett and 
Visscher, 2006). During maturation of keratinocytes, various structural proteins and lipids are 
synthesized and expressed. Keratinocytes are nucleated, but in their final steps they undergo 
changes in their structure, resulting in a transformation into flat anucleate cells of SC (Baroni 
et al., 2012). After the nucleus is digested and the cytoplasm disappears, the lipids are 
released into the intracellular space. The keratin filaments aggregate to form microfibrils and 
the cell membrane are replaced by cross-linked protein with lipids covalently bonded to its 





In the epidermis, beside the keratinocytes, melanocytes and Langerhans cells are two other 
important cell types. Melanocytes are pigment producing cells found in the basal layer of the 
skin. They make melanosomes, which are melatonin-containing granules.  To provide some 
protection to the nucleus from ultraviolet light, melanosomes are transferred from the 
melanocytes to the epidermal keratinocytes. Besides providing protection from the light, this 
also gives the skin its color. The process of melatonin synthesis occurs continuously as the 
epidermis renews, but by exposure to the ultraviolet light this process can be enhanced, to 
produce tanning (Wickett and Visscher, 2006) 
 
Langerhans cell are dendritic immune cells which plays an important role to the immune 
function of the epidermis and also participate in contact allergy (Wickett and Visscher, 2006).  
 
Approximately every 28 days, our skin completely renews, by a balanced process between 
proliferation of the skin and desquamation in a healthy epidermis. When the balance of this 




2.1.2. Dermis  
The dermis is highly vascularized layer that provides nutrition; not only to itself but also to 
the epidermis layer that lacks blood vessels.  It also contains a layer of connective tissue that 
includes collagen and elastic fibers which provides the strength and smoothness. In the 
dermis, sweat glands, hair follicles, sebaceous glands are found (Baroni et al., 2012, Jensen 
and Proksch, 2009). Other components found in the dermis are fibroblasts, mast cells, plasma 
cells, and lymphocytes, and sensory nerves. The thickness of the dermis various with the body 
site, and are between 0.5-5 mm. The dermis is divided into two main layers (Lai-Cheong and 
McGrath, 2013);  
 A thin papillary layer which is richly supplied by blood vessels and sensory nerve 
endings.  
 Reticular dermis, which is in contact with the subcutis  
Subcutis is the innermost layer of the skin. It is composed of lipocytes which are arranged 
into fat lobules and are separated from each other by fibrous septae (Lai-Cheong and 




2.1.3. Routes of penetration in the skin 
Two routes  of penetration through the intact skin is known the  transepidermal route (through 
the intact SCC) and transappendageal (through the sweet gland and hair follicles)  
(Scheuplein, 1965).  The transepidermal pathway divides into two micropathways; the 
intercellular route and the trancellular pathway. In the transepidermal pathway, penetrations 
occur through the lipid domains, while in trancellular penetration occurs first through the 
keratinocytes and then in across the intracellular lipids (Barry, 1991).     
 
 
Figure 3: Routes of penetration through the skin (Barry, 1991) 
 
 
2.2. Wound  
A wound is a rupture or damage in the epithelial integrity of the skin.  It may be accompanied 
by the disruption of the structure and function of the normal skin. When an injury to the skin 
occurs, it triggers a complex series of events (e.g. cell division, chemotaxis, 
neovascularization) which are regulated by many mediators (e.g. inflammatory cells, growth 
factors, cytokines). There are two types of wound, acute wound and chronic wound. Chronic 
wounds occur when the normal process of healing is disrupted at one or more stages. This 
leads into delay in the healing. (Enoch and Leaper, 2008). Chronic and acute wound, both are 




Staphylococcus aureus is found in the majority of wounds, but there are other common 
wound bacteria such as Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia 
marcescens (Percival et al., 2012b).  Staphylococcus aureus is a colonizer of the skin where 
30-60 % of the human population carrying the microorganism. S.aureus is a precipitating 
agent of minor self-limited skin infection. S. epidermidis is most prevalent bacterium of skin, 
representing 90 % of the microflora and therefore is a skin contaminant isolated during 
infections. (Percival et al., 2012a). Pseudomonas aeruginosa is a gram negative bacterium 
and is rarely found in acute wound, but is found in chronic wound. (Bjarnsholt et al., 2008).  
 
 
2.2.1. Wound healing 
Wound healing is a survival mechanism which occurs immediately after the body is injured. 
During the healing process, the damaged or destroyed tissues in this process are removed and 
the integrity of the tissues is restored (Beldon, 2010). Wound healing can be classified into 
three types; primary, delayed primary and secondary healing. 
 
Primary healing occurs where the wound edges are close together, which occurs within 12-24 
             c         U     y   ’    c       c                g c   wound; where the wound 
edges are closed by using the sutures, tissue glue taps or a mechanical device. (Enoch and 
Leaper, 2008).  
 
Delayed primary healing occurs when wound is not closed immediately and becomes 
contaminated.(Enoch and Leaper, 2008)  
 
Secondary healing is seen after the surgical procedures, in major trauma, and severe burns. It 
occurs in wounds with extensive loss of tissue (Enoch and Leaper, 2008). Such wounds are 
vulnerable to infections and their healing process is slow. Vascular and diabetic ulcer are 
examples of such wounds (Beldon, 2010). 
  
The mechanism of wound healing is divided into 4 overlapping stages; haemostasis, 





Haemostasis: to reduce blood loss when an injury occurs, the first response to an injury is 
vasoconstriction. The platelets within the blood adhere to the wall of the blood vessels and the 
collagen exposed, which triggers the release of numbers of inflammatory mediators, cytokines 
and growth factors. This leads to more aggregation of the platelets and triggers coagulation by 
leading to fibrin clot formation. The healing cascade initiated by the growth factors, initiates 
further an chemotaxis reaction involving neutrophils, macrophages muscle cells and 
fibroblasts (Beldon, 2010).     
 
Inflammation: when the coagulation cascade is initiated and as a response to an injury, 
several vasoactive cytokines such as histamine and prostaglandins are released. In response to 
these releases, a local vasodilation and capillary permeability occurs. Monocytes along with 
serous fluid leaks/migrate into the wound, resulting edema. During the inflammatory period, 
neutrophils which are responsible to clean the wound accumulate in the wounded area and 
ingest via phagocytosis the bacteria. The cleaning continues after the neutrophil filled with 
bacteria undergoes apoptosis. To attract more fibroblast and smooth muscle cells to the 
wound, macrophages release some growth factors. This process takes 2-3 days in an acute 
wound, but if contamination occur, the process will be prolonged (e.g. chronic wound) 
(Beldon, 2010).  
 
Proliferation: The inflammation and proliferation phase overlaps with each other, the last 
may last for 2-4 weeks. The proliferation phase is divided into two parts, fibroblast migration 
and formation of the extracellular matrix. Fibroblasts are attracted to the wound area by 
numbers of growth factors, resulting in a production of various components (e.g. proteins, 
collagen). This leads to formation of extracellular matrix.(Enoch and Leaper, 2008) 
 
Remodeling and scar maturation: The extracellular matrix in this phase is remodeled and 
synthesized. The balance between synthesizing and breaking down collagen as the 
extracellular matrix is remodeled leads to equilibrating to steady state about 21 days after 
wounding.  (Enoch and Leaper, 2008).  An interaction between fibroblasts and the 
surrounding extra cellular matrix leads to a wound contraction which is influenced by 
numbers of growth factors, cytokines, platelet-derived. As the scar matures, fibronectin and 
hyaluronan are broken down, while collagen bundles increases in diameter, however these 





Factors that impede wound healing are divided into two, local factors and systemic factors.  
Local factors can be an infection, increased skin tension, inadequate blood supply and poor 
venous drainage. Systemic factors can be; obesity, malnutrition, advancing age and general 








Biofilms are major concern do to their ability to tolerate antibiotics and to gain resistance and 
are main cause of limitations in current chronic wound therapies. It was not before the 1980s 
and 1990s that general opinion was that bacteria are organized in such sophisticated manner 
(Costerton et al., 1999). Before treating some types of infections, such as chronic wound 
infections, it is important to have an understanding of biofilm and how they function to be 
able to treat its causes properly. The mechanism for resistance to antibacterial agents can be 




through the biofilm matrix, (2) altered growth rate of biofilm organisms, and (3) other 
physiological changes due to the biofilm mode of growth (Donlan and Costerton, 2002).  
Biofilms differ from floating bacteria or planktonic bacteria in many ways, for example, their 
structures, interaction with the host, gene expression and their antibiotic resistance is different 
(Zhao et al., 2013). For example Pseudomonas aeruginosa which is one of the 
microorganisms found in chronic wound have been observed in many studies to play a role in 
delaying wound healing process. Their ability to form biofilms (extracellular polymeric 
substance (EPS)-encapsulated biofilms) is thought to be the main reason. (Bjarnsholt et al., 
2008). The EPS contains polysaccharides, alginate, extracellular DNA, and other components 
such as proteins and lipids. Alginates prevents phagocytosis, binds many cationic antibiotics 
and enhance the structure of the biofilm (Bjarnsholt et al., 2008).  
 
2.4. Chitosan  
Chitosan is a derivate of natural polymer chitin, which has gained a huge interest in different 
fields, such as biomedicine, pharmaceutical and food industry. What makes chitosan 
interesting is its properties and natural source. Chitin, the starting material in isolation of 
chitosan is found predominantly in the shells of crustaceans, such as crabs and shrimps, which 
are easily available at waste from seafood processing industries and raw material suppliers 
such as Chitinor AS, in our case. Also there are other sources which may be used for chitin 
production such as krill, crayfish, insects, clams and fungi (Liu et al., 2011, Rinaudo, 2006, 
Jayakumar et al., 2010).  
 






2.4.1. Properties of chitosan  
The properties of chitosan such as the solubility, biodegradability, biological activity and 
chemical reactivity are influenced by the degree of acetylation (DD), its molecular weight and 
the degree of substitution (Jayakumar et al., 2010).  
 
Solubility: the solubility of chitosan in acidic acid (pH<6.5) can be explained by its chemical 
structure. The chemical structure of chitin and chitosan is quite similar, but the amino group 
which is present in chitosan is different than the one present in chitin. This amino group, 
present in chitosan, can be protonated which explains its solubility in diluted acetic acid 
(pH<6.5) in contrast to chitin (Liu et al., 2011, Leedy et al., 2011).  
 
Complex formation: chitosan is used as purifying agent of waste waters, due to its ability to 
form complexes. 
 
Microbial activity: The antibacterial and antifungal properties which these cationic polymers 
have can be explained by two mechanisms; a mechanism that involves the charge and the 
second mechanism that involves the ability of the amino groups to bind to DNA in the cells. 
The positively charged polymer interacts with negatively charged groups which may be 
present on the surface of the cell wall. This interaction prevents important and essential 
materials to enter the cell. While the protonated amino group binds to the DNA, which leads 
to inhibition of microbial RNA synthesis (Liu et al., 2011) 
 
Mucoadhesion: the glycoprotein which is negatively charged and the positively charged 
chitosan interact in acidic conditions, which lead to adhesion (Aider, 2010, Liu et al., 2011). 
This can for example  prolong the retention time of drugs at the mucosal site such as oral or 
vaginal cavities, as well as wounded site (Wang et al., 2011). 
 
Biodegradable: beside the amino group, it also contains a polysaccharide forming nontoxic 
oligosaccharides (Muzzarelli, 2009, Liu et al., 2011)   
 
Haemostatic: some articles have explained that the interaction between the negatively charged 
red blood cells, and positively charged chitosan (in acidic condition) is the mechanism behind 




chitosan a good choose when a drug delivery system is designed for wound dressing 
purposes. There are many chitosan-based bandages and wound dressings available on the 




2.4.2. Potential and limitations of chitosan:  
As discussed so far, chitosan has many properties which explain the increased interest in 
many different fields. Because of its film forming properties chitosan is used to prepare films, 
fibers and hydrogels (Rinaudo, 2006, Liu et al., 2011). The biodegradable properties if 
chitosan and also their antibacterial, antifungal activities make the polymer interesting 
material in both food and pharmaceutical industry.  
Chitosan can be modified chemically to make it more soluble in water, for example by 
introducing different functional groups. A well-known derivate of chitosan are O-and N-
carboxymethlchitosans (Rinaudo, 2006, Jayakumar et al., 2010, Liu et al., 2011). O-and N-
carboxymethlchitosans are water soluble in wide pH range. By chemically modifying the 
original structure it is possible to control its cationic character which leads to an improvement 
in  the  stability of ionic complexes (Liu et al., 2011). Because of the opportunity to modify its 
structure this cationic polymer is interesting for many applications; however, the toxicity 
issue should not be overlooked when new modifications are made.  
The cationic character that this naturally occurring polymer has made it a good choice for 
gene delivery. However, the instability and its low buffering capacity limit its wider use (Liu 
et al., 2011).  
 
Two of the major limitations of chitosan as drug delivery systems are: 
  The solubility (Dai et al., 2011) which is pH-dependent. For instance in physiological 
environment the amino groups will be partially protonated which leads to poor 
solubility (Liu et al., 2011). This limits the possibly applications areas where chitosan 
could be used in. 
  Another limitation of chitosan is the poor mechanical strength of chitosan-based 
formulations when chitosan is used as a single gel-forming agent. This limitation can 
be overcome by using different delivery systems incorporated in chitosan gel matrix 




2.5. Aminolevulinic acid (5-ALA) 
2.5.1. General 
Aminolevulinic acid is a natural compound that plays role in heme biosynthesis. The 
photosensitive compound which forms in heme synthesis, protoporphyrin IX (PpIX), is used 
in various therapies such in bladder cancer and in some topical treatments. For therapeutic 
purposes ALA can be administrated both systemically and topically. As shown in Figure 6 
ALA is a polar molecule and in natural pH occurs mainly as charged zwitterion, the fact that 
bears several limitations, such as reducing bioavailability and lipid solubility. To overcome 
these limitations, along with reduce the light sensitivity after intravenous treatment, many 
attempts have been conducted to modify the structure to improve the bioavailability. Two of 
the most successful ALA derivatives are methyl aminlolevulinate (MAL) and hexyl 
aminlolevulinate (HAL). (Wachowska et al., 2011) 
 
 
Figure 6: Aminolevulinic acid (5-ALA)  
 
 
Metvix ® is the first 5-ALA derivate approved to be used to treat actinic keratosis (AK), 
when other treatments do not provide good results and to treat basal cell carcinoma (BBC). 
Another 5-ALA derivate, HAL (Hexcix®) is also approved for detection of bladder cancer. A 
study to evaluate 4 treatments with different MAL concentration (80 versus 160 mg g
-1
) and 
application duration (1 versus 3 hours) to treat AK were performed. Scales and crust were 
removed from lesions before using light (600-700 nm. 75 J [cm 
2]-1
). The results showed that 
treatment with 160 mg/g MAL cream for 3 hours is slightly better (67 % response) than the 
other treatments (57-66 % response). A further treatment after 3 months produced an even 
better response for treatments with 160 mg/g MAL (90 %) compared with the other 
treatments (80-87 %). Another study investigated if the treatment efficacy of 160 mg/g MAL 
well be improved if the application time (1, 3, 5 or 18 h) of the drug is increased. The study 




significant improvement observed after 3 months which indicated that durations longer than 3 
hours did not improve the clinical response (Fotinos et al., 2006). 
 
2.5.2. Heme, biosynthesis and function  
Heme is an essential molecule to many organisms such as bacteria, archaea and plants. Their 
growth relays on heme which makes it attractive target for antibacterial drug and herbicide 
treatments. The heme molecules play many roles in a living organism for example many 
enzymes relay on heme as prosthetic group, or serves as sensors for diatomic gasses in signal 
transduction pathways. The heme biosynthetic pathways differ in some ways depending 
which living organism is represented but mostly. ALA acts as an intermediate in the heme 
biosynthesis. ALA is normally synthesized in mitochondria by a reaction catalyzed by ALA 
synthase (ALAS), between succinly-CoA and glycine. ALA reaches to cytosol, where it leads 
to formation of prophobilinogen (PBG). Further reaction involving prophobilinogem 
deaminase (PBDG) leads to formation of urophorphyrinogen III. The product forms 
coproporphyrinogen, transports to mitochondria to further conversion to 
protoporporphyrinogen IX. Next step in the heme synthesis is formation of protoporphyrin IX 
(PpIX) and further reaction with ferrochelatase (FECH) leads to formation of heme molecule 








Figure 7: Schematic illustrating the interaction of the heme biosynthesis pathway with exogenous ALA or MAL 
to give intracellular PPIX Heme biosynthesis (Dai et al., 2009) 
 
 
PpIX is a strong photosentiziser which leads to damage the cell after light exposure 
(Wachowska et al., 2011) 
2.6. Photodynamic therapy 
2.6.1. Introduction  
Photodynamic therapy (PDT) has become an important therapeutic option which has been 
used in the past several years as a treatment for various conditions (e.g. infections, bladder, 
skin, and lung cancers) (Chatterjee et al., 2008). The principle of PDT involves the use of 
non-toxic photosensitizers (PS) in combination with the right wavelength visible light to 
excite the PS. This combination in presence of oxygen, produce cytotoxic species that are able 
to kill cells (Hamblin and Hasan, 2004, Dai et al., 2009). The ideal PS should be easily 
synthesized, stable composition, non-toxic, photostable and have minimal self-aggregation 
tendency. PDT in general has many advantages such as; 




 Do not require patient compliance 
 Inexpensive 
 Provides instant results  
 Eliminates development of resistance  
 Eradicates pathogens in biofilms  
 
For antimicrobial PDT, the advantages of using PS containing nanoparticles include; 
 Improves selectivity of the treatment by localizing delivery systems. 
 limit the ability of the cell to pump the PS out (Sharma et al., 2012)  
 
2.6.2. Photosensitizer (PS)  
Porphyrins, chlorins, bacterichlorins and phthalocyanin are the main groups used in PDT 
(Benov, 2014) . 
 
Figure 8: The  main groups used in PDT (Benov, 2014). 
There are other types PS such as, hematoporphyrin (HPD) which is water-soluble compound.  
benzoporphyrin (BPD). (Sharma et al., 2012). In general an ideal photosensitizer should be 
well-defined chemical compound with a strong selective phototoxic effect and have an ability 
to form active oxygen.  Four types of interactions between the PS and nanoparticles have been 
reported: (1) PS embedded in polymeric nanoparticles, (2) PS covalent bonded to the surface 
of NP, (3) PS non covalent bound to nanoparticles and (4) the nanoparticles is itself a PS 





2.6.3. Mechanism of action 
The mechanism of action of PDT can divides into three phases; (1) the PS is localized in the 
targeted cells, (2) visible light is applied to activate the PS and the end (3) results in cell 
damage. The chemically reaction that occurs is divided into two types:  
 
Type I: through electron transfer reactions, ROS is generated by a reaction between H2O2 and 
pictogram concentration of ferrous iron, cuprous copper or transition metals in a Fenton – like 
reactions yield a hydroxide ion and OH. Generating the OH in the cytoplasm leads to 
destruction of necessary proteins for homeostasis (Sharma et al., 2012).  
 
Type II: occur when singlet oxygen, 
1
O2, reacts with double bonds or sulfur atoms resulting in 
an oxidation of macromolecules (Sharma et al., 2012).  
 
 
2.6.4. Drug delivery and routes of administration in microbial cells 
In infections the PS is delivered to the infected area by topical application installation, 
interstitial injection or aerosol for airways-based infections(Sharma et al., 2012). Bacteria 
cells differ from cancer cells in their membranes which are more negative charged. This leads 
to a possibility to achieve a selective antimicrobial PS accumulation after local delivery by 
using positively charged PS. 
Gram positive bacteria have a cytoplasmic membrane which makes it venerable to PDT. They 
are killed by cationic, anionic or neutral PS. Gram negative bacteria can only be killed by 
cationic PS or by method that allows the nonionic PS to be transported in the cell. What 
makes gram negative hard to kill can be explained by their  membrane that differs from gram 
positive bacteria where the PS cannot inter through the cell wall  (Sharma et al., 2012) 
 
 
2.6.5. Nanotechnology in PDT  
In the past years, the interest of nanotechnology in various fields have increased (e.g. 
medicine, diagnostic, imaging and drug delivery) (Barratt, 2000, Freitas Jr, 2005, Sonvico et 
al., 2005). Nanotechnology can be defined as a technology that permits manipulation, 




nanoparticles) (Singh and Lillard Jr, 2009). One of the main problems to overcome in PDT is 
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(e.g. infected or tumor cells) in a therapeutic concentrations with none or little uptake by other 
cells. The goal is a safe and effective use of PDT. Many PS agents are highly hydrophobic 
and insoluble in water(Gupta et al., 2013). In our case we have a hydrophilic PS, but due to 
low capacity to cross biological barriers a carrier is needed(Fotinos et al., 2008). This increase 
the need for a protecting carrier that provides protection from forming aggregates in aqueous 
environments (Gupta et al., 2013). By encapsulation of the PS molecule in an appropriated 
carrier, these issues may be overcome. The delivery system needs to assure the controllable 
delivery of incorporated PS. There are different nanocarriers used by PDT and they are 
summarized below (Gupta et al., 2013):  
- Lipid-based nanoparticles (e.g. liposomes, lipoplexes and nanoemulsions) 
- Polymeric nanocomposites; (chitosan, alginate, collagen) 
- Carbon             ’  (carbon) 
- Silica-based nanoparticles (e.g. silica) 
- Metal nanoparticles (e.g. gold and silver nanoparticles)  
-     c    c                ’      q       D    (e.g. TiO2 and ZnO) 
- Upconverstion nanoparticles (e.g. sodium yttrium fluoride) 
- Magnetic nanoparticles (FeCl2 which is a magnetic core) 
- Lipoprotein nanoparticles   
- Self- illuminating nanoparticles (e.g. BafBr/Eu2+)  
 
Using nanotechnology is a promising approach, but the lack of information on the effect of 
the nanoparticles on human health and environment raises concern to some scientist, despite 
waste majority being supportive of the use.  
 
Using nanotechnology in a combination with PDT has many advantages (Chatterjee et al., 
2008). Improving solubility is one of the advantages which can be reached by using 
nanotechnology to improve solubility of a drug. This can be obtained by encapsulating the PS 
which also improves their stability. Another advantage which this technology provides is the 






2.6.5. Clinical evaluation of PDI in wound treatment   
To determine if PDT can reduce bacterial load in a chronic leg ulcer and potentially lead to 
accelerated wound healing a randomized placebo-controlled study were performed. Patients 
with 16 venous le ulcers and 16 diabetic ulcers were enrolled into this study. For each ulcer 
type two groups were formed, were one group received a PDT treatment with the active 
ingredient (PPA904) and the other they received a PDT treatment with placebo.  The results 
showed a broad and significant bacteria cell kill and a promising trend towards wound 
healing.  (Morley et al., 2013) 
Another study based in using 5-ALA       ’      v                           c     g    
positive and negative bacteria was published in 2007. This study showed that 5-ALA and its 
derivate have a significant effect on gram positive and gram negative bacteria, but gram 
negative bacteria shows more resistance in contrast with the gram positive. This issue may be 
overcome by using polycationic polymers that binds to the gram negative membrane (Fotinos 
et al., 2008).    
 
2.7. Lecithin-chitosan based nanoparticles  
Lecithin chitosan based nanoparticles have become an alternative for colloidal carrier system 
to polymeric nanoparticles, liposomes, nanoemulsions and solid nanoparticles (Hafner et al., 
2011). These nanoparticles are obtained from the supramolecular self-organizing interaction 
of negative lipid material in presence of the positively charged polysaccharide. They are 
prepared by injecting the soybean lecithin alcoholic solution directly into chitosan water 
solution. The sizes obtained from this method along with the surface charge depended on the 
content of the lecithin.   (Sonvico et al., 2006). 
 
The potential of lecithin-chitosan nanoparticles as a colloidal nanosystem for transdermal 
melatonin delivery were investigated by Hafner (Hafner et al., 2011). The study concluded 
that lecithin chitosan nanoparticles have proved to show a promising colloidal nanocarrier for 






2.8. A new chemical entity  
The new chemical entity which will be studied in this project is thought to have antibacterial 
effect.  The substance is a derivate of 5-aminolevulinic acid and has a good solubility in water 
(3.6 g/g water). The pH measured in 10% and 30 % solution is 1.3 and 0.8 respectively. Main 





3. Aims of the study  
The main aim of this project was the development of a suitable carrier for the NCE which 
may have microbial properties which makes it suitable for topical treatment. In this project we 
well develop and optimize chitosan-lecithin-based nanoparticles, and investigate the particle 
size, size distribution, and zeta potential and entrapment efficiencies.  
 
The specific aims in more details were:  
 Development of nanoparticle formulations by optimization of preparation method in 
regard to NCE entrapment efficiency and size distribution  
 Evaluation of nanoparticles stability under two different storage conditions.  
 Evaluation of nanoparticles stability by using zeta potential as an indicator.  






4. Materials and Methods 
4.1.1. Materials  
Acetonitrile, CHROMASOLV® for HPLC, gradient grade, Sigma-Aldrich, Chemie 
GmbH, Steinheim, Germany 
Ammonium acetate, UWR BDH PROLABO, Leuven, Belgium 
Chitosan S, Chitopharm M, Chitinor AS, Haugesund, Norway 
Dialysis tubing, Molecular weight cut-off 12-14000 Daltons, Medicell international Ltd, 
London, UK 
Distilled water  
International Disposable culture tubes borosilicate glass, Kimble Chase, USA 
Ethanol Sigma Aldrich, St. Louis, USA 
Hydrochloride acid 37 %, VWR international BUBA, Leuven, Belgium 
Lipoid S 100, (soybean lecithin, 100 % phosphatidylcholine), Lipoid GMBH, Ludwigshafen, 
Germany 
Methanol CHROMASOLV® for HPLC, Sigma-Aldrich, Chemie GmbH, Steinheim, 
Germany 
Buffer solution, pH 4 and 7, AVS Titrinorm®, VWR BDH PROLABO, Leuven, Belgium  
 
4.1.2. Instruments  
Beckmann L8-70M Ultracentrifuge, Beckmann Instruments Inc., Palo Alto, USA 
Beckman SW 60 Ti rotor, Beckman coulter, Beckman Instruments, Palo Alto, USA  
B  c  ™ R A D A  y    c   c      ,  O  89  000,     x, F   c  
Branson 5510-.MT, Branson Ultrasonic cleaner, Danbury, USA 
Distilled water, Milli.Q Biocel, 0.22µm, Bergman AS, Tromheim, Norway 
Magnetic stirrer from IKA, type RCT basic, Stefen, Germany  
NICOMP Submicron particle sizer, model 370, Nicomp Particle Sizing systems, Santa 
Barbara, USA  
pH Meter 744, Metrohm, Metrohm AG, Herisau, Switzerland  
Sequant® ZIC®-HILIC PEEK Column 150x4.6mm 3.5µm 200Å, from Merck,  
Darmstadt, Germany Waters e2795, separation module, Waters Corporation, Milford, USA 
Waters UV/VISBLE detector, Waters 2489, Waters Corporation, Milford, USA  





4.1.3. Computer programs  
High Performance Liquid Chromatography: Empower 3 Chromatography software (Build 
3471), Milford, USA  
Zeta potential: Zeta potential report version 2.2, Malvern Instruments Limited, 
Malvern, UK 
Windows CW370 Software, NICOMP Particle sizing Systems, CW388 Version 1.68, 
Santa Barbara, USA  
 
4.2. Methods 
4.2.1. Preparation and characterization of nanoparticles  
4.2.1.1. Preparation of empty nanoparticles  
Nanoparticles were prepared by the modified method of Sonvico et al (2006). Empty 
nanoparticles (50 ml) were prepared by adding 2 ml of chitosan solution in hydrochloride 
solution (1 %, w/v) or 0.5 % acetic acid (1 %, w/v) to 44 ml of distilled water, followed by 
injection of 4 ml lecithin ethanol solution (2.5 %, w/v). Two different injection rate were 
used, namely 34 and 2 ml/min. The mixture was stirred for approximately 1 hour and left in 
the refrigerator at least 24 hours before further investigation.  
 
4.2.1.2. Preparation of nanoparticles containing new chemical entity (NCE) 
Lecithin/chitosan nanoparticles (NP) containing NCE were prepared according to the method 
previously reported by Sonvico et al (2006). The only modification was that we dissolved 
chitosan in acetic acid rather than in hydrochloride acid. Ten, 30 and 100 mg of NCE 
respectively were dissolved in 4 ml of lecithin ethanol solution (resulting in 2.5, 5 and 10 % 
solutions) before injecting the solution (injection rate 34 ml/min) into chitosan solution in 
acetic acid under continuous magnetic stirring. The mixture was stirred for approximately 1 
hour and left in the refrigerator for at least 24 hours before further investigation.  
 
4.2.1.3. HPLC analysis 
The HPLC analysis was based on the method described by the company Photocure AS with a 
slight modification on the injection volume (20µl). A metal free HPLC column (Sequant® 
ZIC®-HILIC PEEK Column 150x4.6mm 3.5µm 200Å, Darmstadt, Germany) were used in 
the measurements. The mobile phases were prepared by dissolving 1.5 g ammonium acetate 




The HPLC measurements setting were as followed:  
 Temperature of the column:   40 ºC 
 Samples temperature    8  ºC 
 Injection volume:    0 μ  
 Flow rate: 1 ml/min 
 Run time: 12 minutes 
 Detection wavelength: 270 nm 
 Injection sequence Blank-standard-Test samples-standard 
 
4.4.1.4. Calibration curve  
To obtain a standard curve, stock solution of NCE was prepared in a concentration of 5 
mg/ml. Six standard solutions of 4, 2, 1, 0.5, 0.1 and 0.05 mg/ml, respectively were prepared 
by diluting the stock solution (5 mg/ml) with appropriate volumes of dilution solvent. 
 
4.2.1.5. Entrapment efficiency determination 
To determine entrapment efficiency for NCE, the unentrapped NCE was separated from 
loaded nanoparticles by ultracentrifugation and dialysis.  
Dialysis was performed in dialysis tubing. Five ml of sample was dialyzed against 100, 200 
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suspension (NPS) was dissolved in1.9 ml of methanol (total volume 2 ml) and used in HPLC 
analysis. Two ml of the dialysis medium was also analyzed along with the 2 ml diluted 
nanoparticle suspension. 
Ultracentrifugation: NPS was centrifuged in Beckman-L8-70M ultracentrifuge for 2 hours at 
10 °C and 165000 g. The pellet formed upon ultracentrifugation was dissolved in 1 ml of 
methanol and used in HPLC analysis along with the supernatant (undiluted).  
 
4.2.1.6. Particle size analysis  
To determine particle size distribution, NICOMP Submicron Particle Sizer model 370 was 
used at an angle of 90 degrees and a temperature at 24 °C ± 1 °C. All preparations were 
carried out in an uncontaminated era using particle-      q        (B  c  ™ R A D A 
dynamic enclosure, NO 189 2000, Cedex, France). The test tubes were prepared beforehand 
by filling them with distilled water and sonicated for 5 minutes using an ultrasonic bath to 




with 0.2 µm size syringe filter. All samples were diluted empirically with filtered distillated 
water until intensity between 250 – 350 KHZ was obtained.  All analyses were performed in 
triplicates with run time of 10 minutes for each cycle.  
 
4.2.1.7. Zeta potential  
To assess stability of nanoparticles, zeta potential of all samples were measured on Zetasizer 
Nano Z2600  
Before performing the measurements the cell was thoroughly washed with ethanol and water 
using an appropriate syringe, to ensure totally wetting of the cell. The number of runs was set 
to 12, each sample measured for 3 runs.  
 
4.2.2. Stability testing  
4.5.1. Real time stability testing of nanoparticles containing NCE  
             c            y       g              c                  ,      c  v  y      0   y   
The changes in the nanoparticles size distributions and drug entrapment were followed. The 
zeta potential of the nanoparticles was also measured before the stability testing and after 30 
days   
 
4.2.3. Statistics 
All data shown are the average of at least three different experiments, except for some 
entrapment efficiency and optimization of particle size. Student t-tests were applied to 
compare results. The p v        ≤ 0 0      c                  c   y   g    c     
 
4.2.4. Evaluation of data 
Student t-test was performed on all the results. The particle sizes were evaluated using 
NICOMP distribution.  
 
There are some data which are not triplicated, such as some of the entrapment efficiency 




5. Results and discussion  
5.1. HPLC  
5.1.1. Method validation 
In this project, the HPLC method development of Photocure ASA Company was used with a 
slight modification in the injection volume. To evaluate the method, 6 different 
concentrations were used to establish a calibration curve (Figure 9). 
The concentration range of 0.05 - 4 mg/ml was found to result in a linear relationship between 




was found to exhibit a good 
linearity (0.9997). 
For the method validation, the limit of detection (LOD) and the limit of quantitation (LOQ) 
were determined. LOD is the lowest concentrations which can be determined as statistically 
different from a blank while LOQ represents the smallest amount that can be consider 
reliable(Armbruster and Pry, 2008). The SD is the standard deviation of the response and the 




Figure 9: Calibration curve of NCE 
 
Our results for the determination of NCE concentrations were within a range of 0.09 to 0.44 
mg/ml, which is above the LOD value (0.7), indicating that our data are highly reliable. Some 
of the results were below LOQ and needed to be considered with precautions.  
 
y = 66347x + 180,42 
















5.1.2. Comments on the HPLC results 
To assure that we indeed were able to separate NCE and the byproduct (ALA-4), we tested a 
mixture of both substances in a 90:10 weight ratio. The mixture was dissolved in dilution 




Figure 10: The NCE and primary reference standard (ALA-4) mixed in 90:10 weight ratios 
 
 
As shown in Figure 10, the ALA-4 elute at approximately 4.6 minutes, while the NCE elute at 
4.1 minutes. The two substances are separated but a better separation method is needed in the 
future in respect to stability studies. The information given from the company, addressed that 
the ALA-4 and NCE have indeed two different retention times, 4 and 7 minutes, but that was 
not confirmed in this project even after repeated testing.   
 
As a second step, empty and NCE containing nanoparticles were investigated by HPLC to 
exclude any interference in the measured results. Results demonstrated in Figure 11 and 
Figure 12 clearly shows that the excipients have a chromatographic peak, with a retention 
time shorter than that of native NCE. This confirms that the ingredients present in the 






















The last step was to investigate the stability of the NCE in dilution solvent and in water. The 
stability of NCE in dilution solvent after 3, 5, 20 and 59.6 hours from the preparation time is 
demonstrated in Figure 13. The chromatogram at 3 hours and after 59 hours shows a growing 
peak in the same retention time. This indicates that the NCE is degraded to another substance. 
The main degradation pattern for NCE is hydrolysis to ALA-4 and dimerization to 
dihydropyazine followed with oxidation (information from the Photocure ASA). The 
suspected degraded product elutes earlier than ALA-4 received from the company. This 
chromatogram indicates that the degradation product in dilution solvent is not ALA-4.  
Unfortunately, the stability in water was not determined to evaluate which degradation 
product is present, due to instrument failure. Wrong storage of the NCE may have affected the 
stability of the substance causing degradation. The substance need to be stored at a cold 







Figure 13: Chromatogram of NCE dissolved in dilution solvent at 3, 5, 20 and 59.6 hours                       
                               
 
 
5.2. Nanoparticles characterization  
The focus in this study was the development of a new delivery system containing NCE 
destined for topical application. A formulation based on solid nanoparticles, namely 
lecithin/chitosan nanoparticles, was selected for this proposes (Sonvico et al., 2006). As a first 
step, we followed the effects of the lecithin injection rate and the acid used to dissolve 
chitosan on the particle size distributions in order to optimize these two factors. The results 
from mixing lecithin/chitosan in 5:1 weight ratios are presented in Table 1. 
 
 





Particle size  










HCL 2 27.9 ± 4.9 4.6 ± 1.5 112.6 ± 1.3 95.4 ± 1.5 0.22  
34 32.9 ± 25.3 9.6 ± 12.4 137.8 ± 24.6 90.4 ±12.4 0.16  
Acetic 
acid  
2 51.3 ± 8.0 9.2 ±2.2 184.8 ± 8.0 90.0 ±2.26 0.23  
34 58.3 ± 7.6 12.6 ±5.2 205.3 ± 22.2 87.0 ± 5.5 0.24  
 
 
Chitosan was dissolved in hydrochloric acid, as reported in the method established for 




The injection rate used along with the choice of the acid has shown an effect on the particle 
size and the polydispersity (PD) of nanoparticles. A slight increase in their size was observed 
when the injection rate increased from 2-34 ml/min. However, the differences were not on 
significant level (p>0.05).   
 
Polydispersity is an indicator of the width of the particle size distribution (R g š ć       , 
1996). A significant reduction of the PD was observed when chitosan/HCL solution was used 
(Table 1). This corresponds to the finding in the previous reports (Sonvico et al., 2006) where 
the reported PD was less than 0.2 (injection rate 40 ml/min). This indicates that the particles 
were more homogeneous in sizes then those prepared with the slow injection rate. On the 
other hand, there were no significant differences in the PD when chitosan/acetic acid was 
used.  
Based on these findings, we have chosen to continue using chitosan/acetic acid for their 
optimal particle size (205.3 ± 22.2 nm) and applied 34 ml/min injection rate in further 
experiments. 
 
The second step in this study was to develop a delivery system containing NCE. The 
separations of the entrapment drug were performed by using ultracentrifugation, when 
dialysis method (Skalko-Basnet et al., 2000) was found to be unsuitable for our samples. The 
results are represented in Table 2.  
 
 









0 100 20 n.d. 
10 100 20 n.d 
30 100 20 * 
100 100 20 4.15 ± 0.23 
n.d. not determined  







The NCE is a hydrophilic drug which explains its low entrapment efficiency (Sonvico et al., 
2006). Provisional experiments showed that encapsulation of metoclopramide HCl, a 
hydrophilic drug, in lecithin/chitosan nanoparticles were nearly impossible (Calvo et al., 
1997). We managed to achieve entrapment efficiency of less than 5 % when 100 mg drug 
concentrations were used.  
   
The determined size distributions of lecithin/chitosan nanoparticles were found to be 
influenced by the amount of NCE incorporated in nanoparticles as demonstrated in Table 3 
 
 
Table 3: Representative size distribution 
 
NCE  
(mg)   
Particle size  








0 58.3 ± 7.6 12.6 ±5.2 205.3 ± 22.2 87.0 ± 5.5 0.23  
10 38.4 ± 8.3 6.7 ±1.5 177.9 ±18.6 92.9 ±1.8 0.25  
30 58.8 ± 2.1 13.9 ± 1.4 214.2 ± 8.8 85.4 ±1.3 0.27  
100 54.3 ± 19.3 15.1 ± 10.4 188.3 ±35.6 84.6 ± 10.4 0.26  
 
 
Nanoparticles prepared with 10 and 100 mg NCE have shown a decrease in size and an 
increase in PD. These findings correspond with to findings by Barbieri et al. (2013). 
However, when 30 mg of NCE was used in the preparation of nanoparticles, an increase in 
size distribution and the PD were observed. These results indicate possibly that the NCE may 
have an influence on the structure of nanoparticles (Barbieri et al., 2013).  
 
Another two parameters which were affected by the concentration of NCE used for the 








Table 4: The influence of the concentration of NCE on zeta potential and pH  
Drug (mg) Zeta potential (mV) pH 
0 - 4,6 
10 2.4 ± 0.4 4.1 
30 3.1 ± 1.2 3.5 
100 17.5 ± 5.8 2.6 
 
 
As demonstrated in Table 4 , the zeta potential increased with the increased NCE 
concentration from 2.4 ± 0.4 to 17.5 ± 5.8 mV (Barbieri et al., 2013). The zeta potential was 
observed to be rather unstable while measuring, especially with the increased NCE 
concentration.  
The NCE has an acidic functional group which explains the decrease of pH with the amount 
of NCE added. When the amount of NCE is increased in the suspension the acidity also 
increased, which resulted in decrease in pH values from 4.6 for empty nanoparticles to 2.6 in 
nanoparticles for which preparation 100 mg NCE was used. 
 
To optimize the new delivery system, in order to increase the entrapment efficiency, various 
factors were investigated. In this study we investigated the effect of the polymer and lecithin 
concentration on the particle size and entrapment efficiency.  
 
A preliminary analysis, multiple linear regressions, was performed on the data to see if 
chitosan and lecithin have any significant effect on the size. The results are represented in 








Figure 14: Multiple linear regressions of empty nanoparticles with different concentration of lecithin and 
chitosan 
 
Lecithin and chitosan were found to significantly contribute to the increase in the size, 
however, due to the limited number of experiments the findings need to be taken with 







The effect of different chitosan lecithin concentration on entrapment efficiency, size and zeta 
potential were investigated. The aim was to increase the size, entrapment efficiency, and to 
investigate the stability of those new formulations.  
 










100 20 100 4.6 ± 0.2 2.6 
100 20 200 12.2 ± 1.2 2.6 
100 20 400 18.4 ± 0.9 2.6 
100 40 400 21.2 ±  0.2 2.6 
100 120 100 5.8 ± 0.2 4.1 
100 120 200 12.0* 4.1 
* The entrapment efficiency was determined in duplicate 
 
As shown in Table 5, the determined entrapment efficiency increased in all formulation from 
4.6 ± 0.2 up to 21.2 ± 0.2 %. Lecithin concentration showed the most significant effect on the 
entrapment efficiency. By increasing the lecithin amount from 100 – 400 mg we achieved the 
entrapment efficiency of 4.6 ± 0.2 to 18.4 ± 0.9 %. Doubling the chitosan concentration alone 
from 20 – 40 mg has resulted in entrapment efficiency of 4.6 ± 0.2 to 5.8 ± 0.2 %. The 
combination effect of lecithin and chitosan were also investigated by preparing chitosan and 
lecithin in 40:400 weight ratios. This combination gave the best entrapment achieved (21.2 ± 
0.2 %). 
 
The zeta potential on NCE-containing nanoparticles varied, even when we tried to control the 
pH of the water used for measuring and for preparation of formulations. The results were 
unfortunately not representative and are therefore not included in this thesis. To investigate 
the source of this instability we suspected other factors such as the pH of the suspension, light 
exposure and temperature changes. The last two factors were investigated and their effects 
presented later in the results.  
 
The pH remained fairly constant in all formulations except in those where chitosan amount 





Last was the effect of lecithin and chitosan concentrations on particle size distribution as 
demonstrated in Table 6. Both lecithin and chitosan exhibited an effect on size distribution.  
 
Table 6: Representative size distribution 
 
C:L weight 
ratio (mg : 
mg) 
Particle size  








20:100 54.3 ± 19.3 15.1 ± 10.4 188.3 ±35.6 84.6 ± 10.4 0.26  
20:200 118.9 ± 34.5 24.4 ± 13.0 305.2 ± 21.1 84.3 ± 4.4 0.31  
20:400 159.7 ± 24.2  18.9 ± 6.1 679.9 ± 153.6 81.1 ± 6.1 0.41  
40:400 157.3 ± 74.6 16.1 ± 10.3 677.0 ± 170.7  83.9 ± 10.3 0.47  
120:100 174.2 ± 21.2 31.8 ± 7.8 767.7 ± 195.0 66.3 ± 8.0 0.46 
120:200 162.0 ± 43.4 21.0 ± 5.0 661.6 ± 286.8 76.8 ± 5.2 0.52  
Notes: C:L, chitosan to lecithin weight ratio; PD, Polydispersity  
 
 
As demonstrated Table 6 the PD increased in all formulations (from 0.26 to 0.52); chitosan 
and lecithin in the 120:200 weight ratios formed the most heterogeneous populations of 
nanoparticles (PD value 0.52). The particle sizes have increased in all formulations. However, 
the sizes are optimal for application to the skin and wound. 
 
5.3. Comments on the instability of the zeta potential 
The instability of the zeta potential was one of the challenges we faced already in the early 
stages of the project. The instability was first suspected to be due to the pH fluctuation of the 
water supply in Drug Transport and Delivery Research Group facilities. We tried using water 
with the same pH value for each measurement. However, the instability in values measured 
for zeta potential continued. This implied that other factors such as the effect of the 
suspensions pH (2.6), light exposure and temperature exposure can also contribute to the 
changeable zeta potential values. To investigate the effect of temperature and light exposure, 
two formulations (20:400 chitosan to lecithin weight ratio) were stored at two different 
temperatures (5 ± and 23 ±1 °C) and were well protected from light. The zeta potential was 





   
Figure 15: The change of the zeta potential stored in two different storage conditions over 4 weeks 
 
Temperature is shown to have significant effect on zeta potential, during 4 weeks of testing 
the zeta increased from 5.6 to 38 mV. This means that the higher temperature results in more 
repulsive particles in contrast with the low temperature. Nanoparticles stored at low 
temperature were stable for 4 weeks and by the end of the 4th week, an increase was 
observed. Chitosan and the degradation product of NCE are suspected to have an influence on 
these instabilities. Chitosan is a cationic polymer, which contains an amino group that can be 
protonated at pH<6.5. The NCE may form a degradation product which may have another 
charge in pH 2.6. Electrostatic interaction between positively charged amino group and 
negatively charged lecithin forms nanoparticles. (Sonvico et al., 2006).  
 
The effect of light exposure has been observed in earlier formulations. In formulations which 
were stored at 5 ±1°C, without protection from light exposure, a change in the zeta potential 
was more rapid than when protected from light (data not shown). In the next step of the 
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5.4. Stability testing  
To evaluate the stability of the formulation, we selected 20:400 mg chitosan lecithin 
nanoparticles (due to their sizes) and performed a stability test in two storage conditions, 23 ± 
1 and 5 ±     ,      c  v  y                        c           g        g               g     
the results are presented in Table 7 and Table 8 
 
Table 7:                                                                    
  
Day 
Particle size  
PD  Temperature 










23 ± 1  
1 220.9 ± 100.0 32.0 ± 18.3 741.8 ± 226.5 66.1 ± 19.8 0.40  
30 167.3 ± 78.0 16.2 ± 11.0 903.9 ± 0.9 83.4 ± 11.2 0.44  
 
5 ± 1  
1 136.8 ± 43.4 16.4 ± 9.6 517.0 ± 62.0 68.45 ± 13.5 0.39  
30 189.1 ± 27.1 22.3 ± 4.2 673.5 ± 163.5 79.1± 3.5 0.41  
 
  
The size and the PD in both storage conditions increased as compared with the freshly 
prepared formulations. This increase however was found to be not on the significant level.   
 
 
Table 8: The entrapment efficiency and zeta potential changes during stability testing 
Temperature (  C) Day Entrapment efficiency (%) Zeta potential (mV) 
 
23 ± 1 
1 18.3 ± 0.2 5.7 ± 0,0 
30 - 38.7 ± 1.2 
 
4 ± 1 
1 18.0 ± 0.2 6.2 ± 0.4 





The zeta potential has   c              c   y      g         y       g                     
c                                           (Figure 15). This indicates that the temperature 
is affecting the stability of the suspension. The entrapment efficiency after 30 days was not 
determined due to the technical problems, but the changes in zeta potential indirectly suggest 
that NCE was more exposed on the out surfaces of nanoparticles. 
Another possibility for the zeta instability is that the degraded product has another charge 
which affects the zeta potential. Chitosan and NCE in low pH (2.9) may undergo more 
protonation which affects the zeta charge.    
 
The findings in stability testing along with previous results indicate a need to address the 
stability issue of both NCE as substance and nanoparticles containing NCE. The effect of 






Our aim in this project was to develop chitosan lecithin carrier for the NCE destined for 
topical treatment. The selected carrier was found not to be optimal with respect to the 
entrapment efficiency. The vesicles we have developed might be more appropriate for more 
lipophilic substances; however, there is a room for improvement and optimization of a 
system. We confirmed that both chitosan and lecithin have effect on the vesicle characteristics 
but other factors such as stirring rate, pH, the choice of the acid and the type of chitosan can 
be also utilized to optimize the carrier system. We have developed a reliable HPLC method 
for NCE; however, the method should be optimized in respect to the separation of intact NCE 







 Chitosan lecithin nanoparticles developed through this project need to be optimized 
due to their instability. The effect of these factors needs to be further investigated and 
optimized  
 pH  
 temperature  
 storage conditions 
 stability   
 
 In the long term perspective, more experiments in long term stability are needed. 
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